Published in J Int AIDS Soc on November 28, 2012
Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS One (2013) 1.00
Shamba Maisha: Pilot agricultural intervention for food security and HIV health outcomes in Kenya: design, methods, baseline results and process evaluation of a cluster-randomized controlled trial. Springerplus (2015) 0.84
HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia. J Int AIDS Soc (2014) 0.82
Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda. PLoS One (2015) 0.81
Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infect Dis (2014) 0.81
Usefulness of a fourth generation ELISA assay for the reliable identification of HCV infection in HIV-positive adults from Gabon (Central Africa). PLoS One (2015) 0.80
Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo. AIDS Res Ther (2015) 0.77
HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya. BMC Res Notes (2014) 0.76
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon. PLoS One (2016) 0.76
HIV drug resistance mutations following poor adherence in HIV-infected patient: a case report. Clin Case Rep (2015) 0.75
Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets. Open Forum Infect Dis (2016) 0.75
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis (2010) 4.41
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther (2008) 4.00
Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis (2007) 3.46
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr (2011) 2.80
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis (2012) 2.26
Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS (2010) 2.14
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med (2010) 2.10
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS (2007) 1.98
Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS (2008) 1.58
Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses (2011) 1.38
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis (2012) 1.36
Confirmation of putative HIV-1 group P in Cameroon. J Virol (2010) 1.36
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol (2006) 1.22
High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. J Int AIDS Soc (2011) 1.21
Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Clin Infect Dis (2012) 1.17
Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality. AIDS Res Treat (2010) 1.16
Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis (2009) 1.12
HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther (2006) 1.09
Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr (2011) 1.02
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther (2011) 0.94
Drug resistance mutations during structured treatment interruptions. Antivir Ther (2003) 0.90
Prevalence, genetic diversity and antiretroviral drugs resistance-associated mutations among untreated HIV-1-infected pregnant women in Gabon, central Africa. BMC Infect Dis (2012) 0.85
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2011) 0.83
Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa. AIDS Res Hum Retroviruses (2008) 0.83
Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon. AIDS Res Hum Retroviruses (2010) 0.82
High HIV Type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, Central Africa. AIDS Res Hum Retroviruses (2009) 0.82
[National coordination of the ambulatory treatment centers (ATC) in Gabon: a new process to conduct the scaling up of care for people living with HIV-AIDS]. Sante (2009) 0.81
Suitability of an open automated nucleic acid extractor for high-throughput plasma HIV-1 RNA quantitation in Gabon (Central Africa). J Virol Methods (2011) 0.79
Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine. Antivir Ther (2011) 0.79
Fruit bats as reservoirs of Ebola virus. Nature (2005) 11.05
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS (2006) 6.46
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35
Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis (2009) 4.24
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet (2006) 4.06
The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS (2002) 4.01
Evolutionary relationships of wild hominids recapitulated by gut microbial communities. PLoS Biol (2010) 4.01
Marburg virus infection detected in a common African bat. PLoS One (2007) 4.01
Hybrid origin of SIV in chimpanzees. Science (2003) 3.75
Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS (2005) 3.52
Human immunodeficiency viruses: SIV infection in wild gorillas. Nature (2006) 3.35
Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS (2004) 3.24
Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS (2003) 3.14
Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr (2005) 3.09
Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis (2002) 2.98
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med (2007) 2.93
Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis (2011) 2.82
Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis (2009) 2.82
Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr (2007) 2.72
Multiple diverse circoviruses infect farm animals and are commonly found in human and chimpanzee feces. J Virol (2009) 2.70
African great apes are natural hosts of multiple related malaria species, including Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 2.60
Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis (2013) 2.53
Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis (2013) 2.51
Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther (2003) 2.40
The natural history of Ebola virus in Africa. Microbes Infect (2005) 2.39
Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants. Proc Natl Acad Sci U S A (2007) 2.07
Genetic characterization of tick-borne flaviviruses: new insights into evolution, pathogenetic determinants and taxonomy. Virology (2006) 2.01
Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology (2007) 2.01
Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS (2007) 1.97
Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS (2003) 1.94
Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees. PLoS Pathog (2008) 1.92
Acceptability and uptake of a package to prevent mother-to-child transmission using rapid HIV testing in Abidjan, Côte d'Ivoire. AIDS (2004) 1.79
A plethora of Plasmodium species in wild apes: a source of human infection? Trends Parasitol (2011) 1.78
Adaptation of HIV-1 to its human host. Mol Biol Evol (2007) 1.77
Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J Virol (2008) 1.76
Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. J Virol (2007) 1.74
Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis (2005) 1.73
18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. PLoS One (2008) 1.69
High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One (2010) 1.68
New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade. J Virol (2004) 1.68
Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther (2013) 1.68
Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr (2006) 1.66
Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol (2009) 1.65
Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol (2003) 1.61
Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS (2003) 1.61
Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol (2007) 1.58
A new strategy to improve the cost-effectiveness of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis testing of blood donations in sub-Saharan Africa: a pilot study in Burkina Faso. Transfusion (2009) 1.57
African monkeys are infected by Plasmodium falciparum nonhuman primate-specific strains. Proc Natl Acad Sci U S A (2011) 1.56
Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS (2011) 1.55
Change in Japanese encephalitis virus distribution, Thailand. Emerg Infect Dis (2008) 1.55
A fresh look at the origin of Plasmodium falciparum, the most malignant malaria agent. PLoS Pathog (2011) 1.54
Thirty years of use and improvement of remote sensing, applied to epidemiology: from early promises to lasting frustration. Health Place (2006) 1.53
Detection of Ehrlichia spp., Anaplasma spp., Rickettsia spp., and other eubacteria in ticks from the Thai-Myanmar border and Vietnam. J Clin Microbiol (2003) 1.53
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr (2002) 1.51
Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. Am J Trop Med Hyg (2006) 1.48
Novel circular DNA viruses in stool samples of wild-living chimpanzees. J Gen Virol (2009) 1.46
Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One (2009) 1.43
Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas. J Virol (2009) 1.42
Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol (2010) 1.42
Monoclonal Gammopathy in HIV-1-Infected Patients: Factors Associated With Disappearance Under Long-Term Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 1.40
Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther (2009) 1.35
IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol (2007) 1.35
Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. J Acquir Immune Defic Syndr (2005) 1.34
The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology (2006) 1.33